HK2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL9937898	1.00	20/20
SCHEMBL9937902	1.00	20/20
SCHEMBL9938423	0.80	19/20
SCHEMBL9938427	0.80	19/20
SCHEMBL9938280	0.76	19/20
SCHEMBL9971339	0.63	19/20
SCHEMBL9938276	0.75	17/20
SCHEMBL9938050	0.71	17/20
SCHEMBL9938053	0.71	17/20
SCHEMBL9938761	0.51	17/20
SCHEMBL9937441	1.00	16/20
SCHEMBL9937446	1.00	16/20
SCHEMBL9971321	0.79	16/20
SCHEMBL9938755	0.51	15/20
SCHEMBL9937824	1.00	14/20
SCHEMBL9937827	1.00	14/20
SCHEMBL9938663	0.73	14/20
SCHEMBL9971331	0.73	14/20
SCHEMBL9937688	0.69	13/20
SCHEMBL9937695	0.69	13/20

Clinical trials — most relevant to HK2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Alpha Ketoglutarate Enhances Geroprotection In Surgery (AEGIS)	PHASE4	RECRUITING
Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes	PHASE4	COMPLETED
Ketohexokinase Inhibition in NAFLD	PHASE2	COMPLETED
A Multi-center 12-week Study of HMS5552 in T2DM	PHASE2	COMPLETED
First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal Cancer	PHASE2	COMPLETED
Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC	PHASE2	UNKNOWN
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers	PHASE1	COMPLETED
The Assessment of Single-Dose Safety,Tolerability, Pharmacokinetics and Pharmacodynamic of Globalagliatin Hydrochloride	PHASE1	COMPLETED
Multi-Tracer PET Assessment of Primary Brain Tumors	PHASE1	COMPLETED
Multiple Ascending Doses of Globalagliatin Hydrochloride in Type 2 Diabetes Mellitus	PHASE1	COMPLETED
Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx	EARLY_PHASE1	COMPLETED
PET/CT to Image Hypoxia in Head and Neck Tumours	EARLY_PHASE1	COMPLETED
Dual PETOvac - Dual Time PET/CT in the Preoperative Assessment of Ovarian Cancer	nan	UNKNOWN
Dried Fruit and Postprandial Glycemia Trial	nan	UNKNOWN
Plasma Mannose Associated Parameter Levels in Nondiabetic Coronary Artery Disease	nan	COMPLETED
The Role of Sugars in Fat Accumulation in the Liver	nan	RECRUITING
Alternative Substrates in the Critically Ill Subject	nan	COMPLETED
Diagnostic Significance of Single Center, Open and Prospective Evaluation of 18F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions and Differentiating Multiple Primary Lung Cancer From Intrapulmonary Metastases of Non-small Cell Lung Cancer	nan	UNKNOWN
18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology	nan	COMPLETED
Effect of Acute Fructose Load in Human	nan	COMPLETED
Utility of PET-MRI in Surveillance of Paediatric Brain Tumours	nan	RECRUITING
Early Versus Late FDG-PET/CT in Bladder Cancer	nan	COMPLETED
Cardiometabolic and Mental Health in the RGV	nan	WITHDRAWN
Biologic Mechanisms for Pain Variation After Physical Activity in Osteoarthritis	nan	COMPLETED
The Effect of Ketone Esters on Forearm Glucose Metabolism	nan	ACTIVE_NOT_RECRUITING
The Role of Pyruvate Kinase M2 in Growth, Invasion and Drug Resistance in Human Urothelial Carcinoma	nan	UNKNOWN
Multi-modality Imaging in the Prediction of Response to Systemic Treatment in Colorectal Cancer	nan	UNKNOWN
Multi-Tracer PET Quantitation of Skeletal Muscle Insulin Resistance in Type 2 Diabetes Mellitus	nan	COMPLETED
13C Pyruvate DNP MR Spectroscopy for Lymphoma Treatment Response Assessment	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a HK2 binder may also engage these)

Protein	Name	Similarity
P27881	—	1.000	P27881 →
O08528	—	1.000	O08528 →
Q1W674	—	1.000	Q1W674 →
A2PYL7	—	1.000	A2PYL7 →
A2PYL6	—	1.000	A2PYL6 →
HK1	Hexokinase-1	1.000	landscape →
Q5RC71	—	1.000	Q5RC71 →
A2PYL8	—	1.000	A2PYL8 →
Q91W97	—	1.000	Q91W97 →
HKDC1	Hexokinase HKDC1	0.997	landscape →
P17710	—	0.997	P17710 →
P05708	—	0.997	P05708 →
P27595	—	0.995	P27595 →
Q3TRM8	—	0.990	Q3TRM8 →
Q9SQ76	—	0.989	Q9SQ76 →
P52790	—	0.989	P52790 →
Q9SEK2	—	0.989	Q9SEK2 →
P93834	—	0.988	P93834 →
P80581	—	0.988	P80581 →
GCK	Hexokinase-4	0.988	landscape →
Q42525	—	0.988	Q42525 →
Q1WM16	—	0.987	Q1WM16 →
P52792	—	0.987	P52792 →
P17712	—	0.985	P17712 →
Q26609	—	0.985	Q26609 →
Q2KNB7	—	0.984	Q2KNB7 →
Q9FZG4	—	0.984	Q9FZG4 →
Q5W676	—	0.984	Q5W676 →
Q9SEK3	—	0.983	Q9SEK3 →
Q8LQ68	—	0.982	Q8LQ68 →